HITRUST Risk-based, 2-year Certification validates PDHI is committed to meeting key regulations and protecting sensitive information

(PRWeb February 10, 2022)

Read the full story at https://www.prweb.com/releases/pdhi_achieves_hitrust_risk_based_2_year_certification_to_further_mitigate_risk_in_third_party_privacy_security_and_compliance/prweb18483735.htm

Global asset management firm BlackRock is reportedly set to offer digital asset trading services…

The post BlackRock to offer crypto trading services to its customers appeared first on Coin Journal.

SYDNEY, Feb 9, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the 2021 CenterWatch Global Site Relationship Benchmark Survey.
CenterWatch, established in 1994, is a global benchmarking authority for the clinical trials sector.

The benchmarking report results reflect how more than 3,700 representatives from clinical trial sites around the world rate their clinical research organisation (CRO) relationships and their responses to the COVID-19 pandemic.

The criteria for benchmarking CROs included:
- Professionalism
- Organizational processes
- Preparedness
- Communications

Site respondents were asked to rank the overall reputation of 29 CROs and rate the relative importance of performance-related attributes.

"Strong site, sponsor, and CRO relationships form the essential foundation on which efficient and effective clinical trials are built. We conduct the CenterWatch Global Site Relationship Benchmark Survey as a service to the industry, highlighting behaviors and approaches that are strengthening partnerships and revealing areas that merit improvement. As COVID-19 has put additional strain on relationships of all types, we also requested feedback on partners' pandemic response in this latest survey," said Cynthia Carter, President, Market Intelligence and Insights at WCG.

Novotech CEO Dr. John Moller said "We are very pleased to be benchmarked as a top 10 CRO among the world's leading CROs. Sites are key to our client's success so being ranked highly by sites for our professionalism, communications, and processes is a major achievement for our global team.

"Novotech serves biotechs globally and we pride ourselves on the depth of relationships that we have built with hundreds of Asia-Pacific sites over the last 25 years. In addition, Novotech has signed 45 Leading Site Partnership agreements over the last 3 years. As part of these agreements, Novotech works very closely with the leading sites in the region to promote their research strengths internationally, while enjoying preferential access to their clinical trial infrastructure.

"With more than 2,000 highly experienced professionals, our clients appreciate our strong site and KOL relationships, our deep regulatory expertise, and our ability to accelerate clinical trials across the Asia Pacific and in particular China.

"Industry-leading technology is at the core of our business and ensures rapid and efficient processes, insightful analytics and reporting, and high quality data and compliance."

Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.

Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.

About Novotech Health Holdings

Novotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech Holdings is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech Holdings is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact

Media Contact
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comNovotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the 2021 CenterWatch Global Site Relationship Benchmark Survey.

Through a most cunning experiment, on February 2nd, 100 Thieves weaved its 2021 LCS esports victory story into a display of the business’s innovation. In the LA organisation’s signature parasocial content fashion, 100 Thieves CEO Matthew ‘Nadeshot’ Haag appeared in a video introducing the org’s 1.1 million Twitter followers to a masterful 75-hour click-and-collect fan […]

Resident Evil 3 remake has sold over five million copies. Now maybe Capcom can buy Nemesis a coat that isn't made out of bin bags.

The post The Remake of Resident Evil 3 Has Sold Over Five Million Copies appeared first on GameSpew.

The battle royale genre has gone from strength to strength on mobile over the past few years. There are games for most tastes, but especially if your tastes... Continue reading

The post The 10 Best Battle Royale Shooters on Android 2022 appeared first on Droid Gamers.

Firm Named No.1 Best in KLAS for Security & Privacy Consulting Services

(PRWeb February 08, 2022)

Read the full story at https://www.prweb.com/releases/impact_advisors_receives_24th_best_in_klas_distinction_in_15_years_more_than_doubling_other_service_providers/prweb18485411.htm

Accepting entries from all over the world for the Annual 2022 Cyber Security Global Excellence Awards

(PRWeb February 08, 2022)

Read the full story at https://www.prweb.com/releases/globee_awards_issues_call_for_world_s_best_cyber_security_company_nominations/prweb18484532.htm

LAS VEGAS – The Source+, an award-winning cannabis company with dispensaries in the Las Vegas Valley and Reno, will support national nonprofit, Minorities for Medical Marijuana (M4MM), throughout the month of […]

When investing, your capital is at risk.  __ Inflation is rapidly increasing worldwide, meaning the value of money is falling by the minute. The UK inflation rate reached a decade high of 5.1% , whilst Europe was ever so slightly behind at 4.9%.  The best way to beat inflation is through investing. The issue is [...]

The post Meet the Founder of Income Marketplace appeared first on Seedrs Insights.

In 2000 we had the “dot-com bowl,” and twenty-two years later it looks like we’re going to have the first “crypto bowl.” Among this year’s Super Bowl advertisers are two crypto companies, Crypto.com and FTX. Advertising during the Super Bowl can put a brand in front of an audience of 100 million people, but placing […]

The post Crypto trading: ‘big fee‘ or ‘no-fee‘ future appeared first on Daily Fintech.

PHOENIX – Feb. 7, 2022 – onsemi (the “Company”) (Nasdaq: ON) today announced its fourth quarter and fiscal year 2021 results with the following highlights:

• Record fiscal year revenue of $6.74 billion representing 28.3% year-over-year growth
• Record quarterly revenue of $1,846.1 million, and record GAAP and non-GAAP gross margins of 45.1% and 45.2%, respectively
• Record quarterly GAAP and non-GAAP operating margins of 26.0% and 28.6%, respectively
• Fourth quarter GAAP and non-GAAP diluted earnings per share of $0.96 and $1.09, respectively 2021 free cash flow increased 167% year-over-year, with fourth quarter at $457.0 million or 25% of revenue

“Our disciplined execution on transformation initiatives in 2021 resulted in record financial performance and achievement of our financial targets ahead of stated timeline. Revenue for 2021 grew 28.3%. Operating income and free cash flow increased 6 times faster than the revenue as we focus our portfolio on secular megatrends of electric vehicles, ADAS, alternative energy and industrial automation. We continue to expand gross margins as we shift our mix into these high-value strategic markets while ramping new products, rationalizing our manufacturing footprint, and improving our overall cost structure. Outlook for our business remains robust as evidenced by over 60% year-over-year growth in our design win